UAB Ligence appears in FDA device records as the applicant for Ligence Heart, a software device classified under the radiology regulation for automated radiological image processing. The manufacturer’s own documentation describes Ligence Heart as echocardiography analysis and reporting software, and its instructions for use carry version-specific revisions. The filings reviewed here span two 510(k) submissions, K253535 and K261733, with decision dates in late 2025 and 2026. The company’s published materials also reference CE marking in the EU, with cleared parameters described as differing by region. [1][2][4][6][9]

Documented product and regulatory identity

FDA records list Ligence Heart under device classification Automated Radiological Image Processing Software, regulation number 892.2050, product code QIH, with the advisory committee recorded as Radiology. The applicant name appears as UAB Ligence in the 510(k) database entry for K261733 and as Ligence Uab in the K253535 record. The manufacturer’s instructions for use identify UAB Ligence at Taikos pr. 54, Kaunas, Lithuania, and describe Ligence Heart as the product covered by the document. [1][2][7][9]

The manufacturer’s website describes Ligence Heart as echocardiography analysis and reporting software for intelligent heart ultrasound image analysis, and states that it prepares measurements for review rather than replacing the cardiologist or sonographer. The same page states the product is FDA cleared and CE marked, and notes that cleared parameters differ by region. [4]

Filing history and dated submissions

The K253535 record identifies Ligence Heart with applicant Ligence Uab and the same device classification name. A company announcement dated November 26th, 2025 states that Ligence Heart received FDA 510(k) clearance, describing the software as automating measurements and analysis of 2D transthoracic echocardiography images and producing a structured report with cardiac structural and functional parameters. [8][9]

A second company announcement dated April 14th, 2026 describes a second FDA 510(k) clearance for a newer iteration of Ligence Heart, adding fully automated Left Ventricular Global Longitudinal Strain analysis and expanded deployment options including private cloud integration, with version 4.0.0 stated as available for US healthcare providers. The FDA record for K261733 shows the submission received on 2026-05-26 and a substantially equivalent decision on 2026-10-07, a Traditional review not reviewed by a third party, with the statement type recorded as Statement. [1][2][5]

Instructions for use and versioning

Published instructions for use exist for multiple versions of Ligence Heart, including 3.42.0, 3.42.1 and 4.1.0. The 3.42.0 document carries update and approval dates of 2026-03-17 and a revision history beginning in 2021. The 4.1.0 US document records a revision history starting 2025-06-12, with a later revision removing a performance table describing ultrasound scanners and transducers used for supportive external component validation and removing certain server-side operating system requirements. [3][6]

The instructions for use describe on-screen display of product information such as product name, software version, release notes, build date, UDI number, certificate and notified body ID, alongside manufacturer name, address, email and website. They also describe decommissioning of on-premise deployments through contact with technical support, and reporting of security issues through a published web page or by email to support or the data protection contact. [3][6][7]

Scope of the reviewed record

The linked FDA collection for this profile contains one 510(k) record, K261733, with a substantially equivalent decision, and the sample of linked records is the same single entry. That count reflects the filings retrieved for this profile as of the stated date and is not a measure of total company sales, total portfolio or safety performance. No recall records appear in the retrieved sample. [1]

The company’s published pages reference partner logos and contact addresses for information, sales, support and its information security officer, and link to policies, a clinical investigation report, grants, release notes and user manuals. Details of ownership, parent entities, customer names and commercial deployment volumes are not established by the reviewed records. [4][8]